This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abeona Therapeutics, Inc.
Drug Names(s): EB201, EB 201, AAV-DJCOL7A1
Description: EB-201 is a novel, AAV-mediated gene editing and delivery approach to correct COL7A1 gene mutations in skin cells (keratinocytes). The inherited disease dystrophic epidermolysis bullosa is caused by recessive or dominant mutations in COL7A1, the gene encoding type VII collagen.
Additional information available to subscribers only: